TipRanks Smart Value #50: Properly Aligned

Shrilekha Pethe on February 17, 2026

Dear Investors,

Welcome to the 50^th edition of our TipRanks Smart Value Newsletter!

This Week’s Top Value Pick: Align Technology (ALGN)

Align Technology (ALGN) is a U.S.-based medical device company specializing in clear aligner orthodontic treatment and digital dental solutions. Its flagship Invisalign system is used by orthodontists and general practitioners to treat malocclusion through custom-designed, removable aligners, which are clear, removable plastic appliances used to gradually straighten teeth. The company also offers the iTero intraoral scanning platform and related software that enhance digital treatment planning and clinical workflows. Align is a global leader in the clear aligner market, serving dental professionals and patients across more than 100 countries.

Scaled Precision

Align Technology was founded in 1997 with the goal of transforming orthodontics through digital technology. The company introduced Invisalign in 1999, pioneering clear aligner therapy as an alternative to traditional metal braces. Early adoption was led by adult patients seeking a more aesthetic option, prompting Align to invest heavily in clinical validation, manufacturing scale, and orthodontist education to build credibility within the dental community.

During the 2000s, Align expanded beyond its initial niche by targeting teenage patients and growing internationally, driving higher case volumes and broader practitioner adoption. A major inflection point came with the development of its proprietary SmartTrack material and SmartForce features, which improved treatment predictability and clinical outcomes. These innovations strengthened Align’s competitive moat and supported pricing power.

The company’s next phase of growth centered on digital dentistry. In 2011, Align acquired Cadent Holdings, bringing the iTero intraoral scanner platform in-house. This acquisition integrated digital scanning into orthodontic workflows, replacing physical impressions and improving case acceptance. Over time, iTero evolved into a strategic growth driver, connecting scanning, treatment planning, and aligner manufacturing within a single ecosystem, while software enhancements expanded Align’s reach into broader dental applications.

Align continued to scale through the 2010s and early 2020s by investing in global manufacturing capacity, automation, and data analytics to support rising case shipments and margin expansion. Despite pandemic-related disruptions, demand recovered as patient visits normalized, allowing the company to leverage its scalable digital platform.

Targeted acquisitions further broadened the ecosystem. In 2020, Align acquired exocad GmbH, expanding into CAD/CAM software for restorative dentistry and dental laboratories. In 2024, it acquired Cubicure GmbH, strengthening direct 3D printing capabilities for more efficient and sustainable aligner production.

Today, Align stands as a global leader in clear aligner therapy and digital orthodontics, supported by proprietary materials, advanced software, and an integrated digital workflow that drives recurring, high-margin growth.

Dental Ecosystem

Align Technology operates a digitally driven dental platform built around clear aligner therapy and intraoral scanning systems. Approximately 80% of revenue is generated by the Clear Aligner segment through the sale of Invisalign treatment cases to orthodontists and general practitioners globally. Each case represents a customized series of aligners designed using proprietary software and manufactured through advanced 3D printing and mass-customization processes. Because aligners are prescribed on a per-patient basis, revenue scales with doctor adoption and patient demand, while pricing varies by product complexity and geographic mix.

The second pillar of the model is the Systems & Services segment, which includes iTero intraoral scanners, service contracts, and CAD/CAM software. These scanners digitally capture dental impressions and integrate directly into Invisalign treatment planning, replacing traditional molds and creating a combination of equipment sales and recurring software and service revenue. By placing scanners inside dental practices, Align strengthens its ecosystem, as iTero is tightly integrated with Invisalign workflows, reinforcing customer loyalty and supporting higher case starts.

A defining feature of Align’s model is its end-to-end digital workflow. The company controls treatment planning software, manufacturing, and key elements of distribution, enabling operational scale and margin leverage as volumes grow. Continued international expansion, broader adoption among general dentists, product innovation across teen and complex cases, and ongoing software enhancements support higher case volumes and premium offerings. Together, the recurring nature of treatment cases and service revenues, scalable manufacturing, and disciplined capital allocation underpin Align’s ability to generate durable operating cash flow.

Aligned Accelaration

This integrated model was reflected in fourth-quarter operating performance. Clear Aligner volumes increased year-over-year across EMEA, Latin America, and Asia-Pacific, while North America remained stable, resulting in the strongest Americas performance since 2021. Growth was broad-based across adults, teens, and children and supported by both orthodontists and general practitioners. Latin America delivered double-digit growth and record shipments, while EMEA posted a record quarter with double-digit expansion. Asia-Pacific also achieved double-digit growth, driven by strong adoption in China, India, and South Korea, particularly among teens and younger children. Sequential momentum reflected adult case growth in EMEA and rising teen and child volumes in Latin America, signaling continued share gains and deeper penetration in emerging markets. In China, potential disruption from volume-based procurement remains limited, as roughly 85% of Align’s revenue is generated through the private sector.

Average selling price (ASP) per case declined during the quarter, driven primarily by promotional discounts, geographic shifts toward lower-priced markets, currency effects, and revenue deferrals. These pressures were partially offset by premium products, higher complexity cases, and selective price increases, suggesting that ASP pressure was tactical rather than structural.

Operational indicators remained constructive. Align recorded a quarterly record of approximately 88,000 submitting doctors globally, driven primarily by orthodontists. Utilization and orthodontic share of business expanded at strong rates in the Americas and EMEA, reinforcing demand durability among higher-volume providers.

Product innovation continues to expand the addressable market. Invisalign First, designed for children aged 6 to 10, gained further traction, while the FDA-cleared removable palate expander emerged as a meaningful adoption driver. Mandibular advancement solutions for jaw correction further broadened clinical use cases. To improve affordability, Align is introducing lower-cost treatment options with fewer refinements. At the same time, investments in direct 3D printing are expected to enhance manufacturing efficiency, with limited releases planned for 2026 and more complex applications targeted for 2027. These initiatives, alongside milestones such as surpassing 1 million cumulative patients treated in Latin America, the UK, and Spain and Portugal, reinforce the company’s long-term growth runway.

Affordability and patient conversion have become increasingly important levers for sustaining volume growth, particularly in a more selective consumer environment. Align is expanding partnerships with third-party healthcare financing providers to enable installment-based payment options, lowering upfront costs for patients. At the practice level, clinicians are encouraged to scan every patient and use chairside visualization tools to demonstrate treatment outcomes in real time, improving case acceptance rates. These initiatives are especially impactful in the teen and children segment, which remains a long-term growth driver. To date, approximately 6.5 million teens and children have been treated with Invisalign, and the number of doctors submitting teen and children cases increased 6% year-over-year, reinforcing steady adoption across both orthodontists and general practitioners.

The Systems & Services segment continues to reinforce adoption by embedding digital workflows into dental practices. Fourth-quarter growth was driven by higher scanner volumes and increased non-system sales, with the iTero Lumina platform accounting for approximately 86% of scanner units sold. Sequential growth was broad-based across regions, reflecting steady global adoption by both orthodontists and general practitioners.

Software is an increasingly important growth lever. The exocad CAD/CAM platform delivered both sequential and year-over-year growth, supported by expanding use in restorative dentistry. Align is piloting its Advanced Restorative Treatment (ART) workflow in Europe, with a broader rollout planned for 2026. ART integrates digital design, scanning, and lab collaboration, simplifying restorative procedures such as crowns and implants. Deeper integration between iTero scanners and Align’s digital suite, including diagnostic tools such as the Oral Health Suite and AI-enabled AXI, supports earlier detection, improved case acceptance, and closer collaboration among general practitioners, orthodontists, and labs.

Strategically, Align is scaling adoption through large group practices, improving affordability, and increasing digital engagement. Dental and Orthodontic Service Organizations (DSOs) now account for roughly 25% of case volumes and are growing at double-digit rates, with top groups in the Americas and EMEA achieving double- or triple-digit growth. Because these organizations operate at scale and tend to standardize digital workflows, they help offset softer demand among smaller, independent practices in North America.

With 22 million patients treated globally and local manufacturing capabilities in key markets, Align combines global scale with operational efficiency. Productivity improvements, equipment upgrades, and favorable product mix are expected to support margin recovery over time, with investments in direct manufacturing slightly dilutive in 2026 before becoming accretive in 2027 and 2028 as scale builds.

Margin Smile

Align’s revenues and EPS have grown at a CAGR of 2.6% and 7%, respectively over the past three years. This growth has been driven primarily by higher Invisalign case volumes, strong international expansion in APAC and EMEA, and continued adoption among teens and children. Earnings growth has been amplified by operating leverage and cost efficiencies, with gross margins reaching 72% and operating margins expanding meaningfully despite modest ASP pressure.

The company closed 2025 with improving momentum, highlighted by steady revenue growth, expanding margins, and strong cash generation in the fourth quarter.

In Q4 2025, revenue reached a record $1.05 billion, up 5.3% year-over-year and exceeding estimates, supported by Clear Aligner revenue, which increased by 5.5% year-over-year to $838 million, supported by record case volumes of 677,000, up 7.7% year-over-year, its strongest growth rate since 2021. The acceleration was concentrated outside North America. EMEA, APAC, and Latin America delivered double-digit volume growth, with Latin America achieving a milestone of 1 million cumulative patients treated. Teen and children reached 230,000 new cases in the quarter, up 7% year-over-year, reinforcing long-term penetration opportunities in younger demographics. Meanwhile, average selling prices (ASP) declined modestly, with Q4 ASP of $1,240 representing a drop of $25 year-over-year, reflecting geographic mix, foreign exchange, and promotional activity.

Systems and Services revenue rose 4.2% year-over-year to $209 million, benefiting from scanner sales and service activity. Clear Aligners continued to account for more than 80% of total revenue, while Systems and Services represented roughly 20%, contributing to ecosystem strength through iTero scanner adoption and CAD/CAM growth. Notably, about 86% of scanner units shipped were the newer Lumina model, supporting digital workflow integration.

Profitability improved meaningfully. Adjusted gross margin reached 72%, the highest level since 2022, benefiting from stronger volume leverage and operational efficiencies. Operating expenses declined on a GAAP basis both sequentially and year-over-year, supporting operating income of $155 million and a 14.8% margin. Adjusted operating margin climbed to 26.1%, the highest level since 2021. Adjusted EPS reached $3.29, up by 35% year-over-year, beating Street estimates. Cash flow from operations totaled $223 million, with free cash flow of $187 million, up by 10.8% sequentially. The company ended the year with $1.09 billion in cash and continued returning capital through share repurchases.

For FY25, revenue reached a record $4 billion, up by ~1% year-over-year. Clear Aligner revenue totaled $3.2 billion, with case volumes rising 4.7% to 2.6 million, including strong growth among teens and children. Systems and Services revenue increased to $790 million, up by 2.7% year-over-year. Adjusted operating margin exceeded expectations at 22.7%.

Looking ahead, management expects revenues to be $1.02 billion at midpoint, up 3% to 5% year-over-year, with continued mid-single-digit volume growth in Clear Aligners, modest revenue growth in the first quarter, and adjusted operating margin to be around 19.5%, consistent with typical Q1 seasonality. For FY26, worldwide revenue growth to be up 3% to 4% year-over-year, with Clear Aligner volume growth to be up mid-single digits year-over-year. Adjusted operating margin to be approximately 23.7%, 100 basis points improvement year-over-year. Guidance assumes stable macroeconomic conditions and no material tariff impact.

In Line

Over the past year, Align Technology’s share price has declined by just over 8%, reflecting a combination of earnings volatility, softer demand for discretionary orthodontic treatments, and broader macroeconomic pressure on consumer healthcare spending. While the Q2 earnings miss triggered a sharp re-rating and weighed heavily on market sentiment at the time, the setback proved to be a one-off. Subsequent outperformance over the following two quarters has reinforced the underlying strength of the business and driven a meaningful recovery in the stock. Even so, valuation metrics have yet to fully reflect this improvement, creating an attractive entry point at current levels.

On an absolute basis, Align is now trading at more than a 45% discount to its own historical valuation averages across multiple metrics, including non-GAAP trailing and forward price-to-earnings ratios, forward EV/EBITDA, price-to-sales, price-to-book, and price-to-cash-flow ratios. In practical terms, investors today are paying significantly less for each dollar of Align’s earnings, revenue, and cash flow than they typically have over the company’s history. This level of multiple compression suggests that the market is already discounting slower growth, near-term demand uncertainty, and execution risk.

At the same time, when Align is compared with large publicly listed dental and orthodontic peers such as Dentsply Sirona and Envista Holdings, its valuation sits in the moderate to high range on several forward-looking measures, including non-GAAP P/E, EV/ EBITDA, price/sales, price-to-book, and price-to-cash-flow ratios. This apparent contrast highlights an important nuance. Align consistently generates higher gross margins, stronger free cash flow, and operates a more asset-light and scalable business model than many traditional dental equipment peers. The valuation premium that remains is meaningfully narrower than in prior cycles, indicating that much of Align’s historical growth advantage is no longer fully capitalized into the stock price.

For value investors, this creates a more balanced risk–reward profile than has been available for much of Align’s public history. The current valuation implies restrained expectations rather than optimism, which can provide a degree of downside protection if growth remains subdued. At the same time, Align does not need to return to peak growth rates to justify upside; even modest volume stabilization, margin normalization, or improved cash flow conversion could support a re-rating toward historical averages.

In effect, Align is transitioning from a pure growth valuation toward a quality-at-a-discount profile. While the stock is not a classic deep-value opportunity, the current pricing reflects a meaningful margin of safety relative to its historical multiples, offering value-oriented investors exposure to a structurally strong business without paying the premium valuations that once defined the name.

Overall, analysts remain optimistic about ALGN as the company’s business model is supported by strong underlying economics, with sustained trailing twelve-month revenue growth of around 45% and gross margins near 70%, reflecting durable demand and meaningful pricing power for Invisalign. These margins provide ample capacity to reinvest in research and development, marketing, and geographic expansion, supporting long-term profitability.

At the same time, the company’s very strong balance sheet, low leverage, and expanding digital ecosystem, including a growing iTero scanner base and deeper DSO adoption, enhance financial flexibility, strengthen customer stickiness, and reinforce recurring revenue and competitive advantages across cycles.

Street consensus implies a roughly 6% upside from the current share price, with more bullish forecasts pointing to potential gains of up to 18%. This dispersion in price targets reflects different assumptions about growth durability, margin recovery, and valuation normalization, rather than disagreement about the core business quality. This optimism is reinforced by discounted cash flow analysis, which suggests Align’s shares may be trading at an estimated 17% discount to intrinsic value, providing valuation support for long-term investors.

Align does not pay a dividend and instead returns capital to shareholders primarily through share repurchases. During the fourth quarter of fiscal 2025, the company repurchased approximately $100 million of its common stock. These buybacks were executed under a $200 million open market repurchase plan that was announced in August 2025 and fully completed in January 2026.

For FY25, Align repurchased a total of $465.9 million of its shares, reflecting continued use of excess cash to reduce share count and enhance per-share metrics. The company’s repurchase activity remains part of a broader, multi-year authorization framework rather than a one-time program.

As of December 31, 2025, Align had $831.2 million remaining under its $1 billion stock repurchase authorization that was announced in April 2025. This remaining capacity provides the company with flexibility to continue returning capital to shareholders, subject to market conditions, cash flow generation, and internal investment priorities.

Investing Takeaway

For value-oriented investors, Align Technology presents a more balanced opportunity than it has for much of its public history. Market concerns around discretionary demand and near-term growth volatility have compressed expectations, shifting the stock away from a pure growth narrative toward a quality-at-a-reasonable-price profile. Importantly, this reset has not altered the company’s underlying fundamentals. Align continues to benefit from a dominant competitive position, high-margin economics, strong cash generation, and a deeply integrated digital ecosystem that supports recurring revenue and customer stickiness. With a conservative balance sheet and ongoing capital returns through buybacks, downside risk appears more contained than in prior cycles. While Align may not appeal to deep-value purists, the current setup offers long-term investors exposure to a structurally strong healthcare franchise at a valuation that is more reflective caution rather than optimism, creating a more attractive margin of safety.

Category: Smart Value